Averhealth — Best practice drug screening products and services

Master Agreement 101425 is a cooperative purchasing contract between Sourcewell, a Minnesota service cooperative, and Avertest LLC (dba Averhealth) for the provision of laboratory and toxicology testing, screening services, and related solutions. This agreement establishes a framework for governmental, educational, nonprofit, and tribal agencies across the United States and Canada to procure best-practice drug screening products and services. The contract is effective for a four-year term starting December 1, 2025, and ending November 30, 2029, with the possibility of three one-year extensions. The scope of work requires the supplier to provide comprehensive testing solutions, including test kits, equipment, and chain-of-custody systems, ensuring high reliability with a target of over 98 percent accuracy on blind proficiency testing and 99.9 percent system uptime. Services must adhere to rigorous quality standards, including CAP-FDT accreditation, CLIA certification, ISO/IEC 17025 standards, and DEA registration. Averhealth, which identifies as a small business with multiple socioeconomic certifications including WOSB and SDB, was selected through a best-value trade-off evaluation that heavily weighted pricing, the depth of offered solutions, and the ability to deliver services. Contract administration is decentralized, with individual participating entities managing their own transactions, inspections, and acceptance of services. Invoicing is handled monthly through the Aversys proprietary system with Net 30 payment terms. The supplier must maintain strict compliance with various federal and state regulations, including the Buy American Act, 2 C.F.R. § 200 for federally funded transactions, and specific record retention requirements of three to six years for audit purposes.